Single nucleotide polymorphisms associated with elevated alanine aminotransferase in patients receiving asunaprevir plus daclatasvir combination therapy for chronic hepatitis C.

by Keizo Kato, Noritomo Shimada, Masanori Atsukawa, Hiroshi Abe, Norio Itokawa, Yoshihiro Matsumoto, Rie Agata, Akihito Tsubota
Published 2019-01-01

Effect of Vitamin D Supplementation on Skeletal Muscle Volume and Strength in Patients with Decompensated Liver Cirrhosis Undergoing Branched Chain Amino Acids Supplementation: A P...

by Tomomi Okubo, Masanori Atsukawa, Akihito Tsubota, Hiroki Ono, Tadamichi Kawano, Yuji Yoshida, Taeang Arai, Korenobu Hayama, Norio Itokawa, Chisa Kondo, Keiko Kaneko, Katsuhiko Iwakiri
Published 2021-05-01

Factors influencing subclinical atherosclerosis in patients with biopsy-proven nonalcoholic fatty liver disease.

by Taeang Arai, Masanori Atsukawa, Akihito Tsubota, Tadamichi Kawano, Mai Koeda, Yuji Yoshida, Tomohide Tanabe, Tomomi Okubo, Korenobu Hayama, Ai Iwashita, Norio Itokawa, Chisa Kondo, Keiko Kaneko, Chiaki Kawamoto, Tsutomu Hatori, Naoya Emoto, Etsuko Iio, Yasuhito Tanaka, Katsuhiko Iwakiri
Published 2019-01-01

Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-worl...

by Taeang Arai, Masanori Atsukawa, Akihito Tsubota, Shigeru Mikami, Hiroki Ono, Tadamichi Kawano, Yuji Yoshida, Tomohide Tanabe, Tomomi Okubo, Korenobu Hayama, Ai Nakagawa-Iwashita, Norio Itokawa, Chisa Kondo, Keiko Kaneko, Naoya Emoto, Mototsugu Nagao, Kyoko Inagaki, Izumi Fukuda, Hitoshi Sugihara, Katsuhiko Iwakiri
Published 2021-03-01

Liver fibrosis is associated with carotid atherosclerosis in patients with liver biopsy-proven nonalcoholic fatty liver disease

by Taeang Arai, Masanori Atsukawa, Akihito Tsubota, Keizo Kato, Hiroshi Abe, Hirotaka Ono, Tadamichi Kawano, Yuji Yoshida, Tomohide Tanabe, Tomomi Okubo, Korenobu Hayama, Ai Nakagawa-Iwashita, Norio Itokawa, Chisa Kondo, Keiko Kaneko, Naoya Emoto, Mototsugu Nagao, Kyoko Inagaki, Izumi Fukuda, Hitoshi Sugihara, Katsuhiko Iwakiri
Published 2021-08-01

Increased Frequency of Dysfunctional Siglec-7−CD57+PD-1+ Natural Killer Cells in Patients With Non-alcoholic Fatty Liver Disease

by Yuzuru Sakamoto, Yuzuru Sakamoto, Sachiyo Yoshio, Hiroyoshi Doi, Taizo Mori, Michitaka Matsuda, Hironari Kawai, Tomonari Shimagaki, Shiori Yoshikawa, Yoshihiko Aoki, Yosuke Osawa, Yuji Yoshida, Taeang Arai, Norio Itokawa, Masanori Atsukawa, Takanori Ito, Takashi Honda, Yoshihiro Mise, Yoshihiro Ono, Yu Takahashi, Akio Saiura, Akinobu Taketomi, Tatsuya Kanto
Published 2021-02-01

Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma

by Makoto Chuma, Haruki Uojima, Kazushi Numata, Hisashi Hidaka, Hidenori Toyoda, Atsushi Hiraoka, Toshifumi Tada, Shunji Hirose, Masanori Atsukawa, Norio Itokawa, Taeang Arai, Makoto Kako, Takahide Nakazawa, Naohisa Wada, Shuitirou Iwasaki, Yuki Miura, Satoshi Hishiki, Shuhei Nishigori, Manabu Morimoto, Nobuhiro Hattori, Katsuaki Ogushi, Akito Nozaki, Hiroyuki Fukuda, Tatehiro Kagawa, Kojiro Michitaka, Takashi Kumada, Shin Maeda
Published 2020-01-01

Potential of Lenvatinib for an Expanded Indication from the REFLECT Trial in Patients with Advanced Hepatocellular Carcinoma

by Susumu Maruta, Sadahisa Ogasawara, Yoshihiko Ooka, Masamichi Obu, Masanori Inoue, Norio Itokawa, Yuki Haga, Atsuyoshi Seki, Shinichiro Okabe, Ryosaku Azemoto, Ei Itobayashi, Masanori Atsukawa, Nobuyuki Sugiura, Hideaki Mizumoto, Keisuke Koroki, Kengo Kanayama, Hiroaki Kanzaki, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Naoya Kanogawa, Tomoko Saito, Takayuki Kondo, Eiichiro Suzuki, Shingo Nakamoto, Akinobu Tawada, Tetsuhiro Chiba, Makoto Arai, Tatsuo Kanda, Hitoshi Maruyama, Naoya Kato
Published 2020-05-01

Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B

by Norio Itokawa, Masanori Atsukawa, Akihito Tsubota, Koichi Takaguchi, Makoto Nakamuta, Atsushi Hiraoka, Keizo Kato, Hiroshi Abe, Shigeru Mikami, Noritomo Shimada, Makoto Chuma, Akito Nozaki, Haruki Uojima, Chikara Ogawa, Toru Asano, Joji Tani, Asahiro Morishita, Tomonori Senoh, Naoki Yamashita, Tsunekazu Oikawa, Yoshihiro Matsumoto, Mai Koeda, Yuji Yoshida, Tomohide Tanabe, Tomomi Okubo, Taeang Arai, Korenobu Hayama, Ai‐Nakagawa Iwashita, Chisa Kondo, Toshifumi Tada, Hidenori Toyoda, Takashi Kumada, Katsuhiko Iwakiri
Published 2021-01-01

What Can Be Done to Solve the Unmet Clinical Need of Hepatocellular Carcinoma Patients following Lenvatinib Failure?

by Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, Kazuya Kariyama, Joji Tani, Shinya Fukunishi, Masanori Atsukawa, Masashi Hirooka, Kunihiko Tsuji, Toru Ishikawa, Koichi Takaguchi, Ei Itobayashi, Kazuto Tajiri, Noritomo Shimada, Hiroshi Shibata, Hironori Ochi, Kazuhito Kawata, Satoshi Yasuda, Hidenori Toyoda, Hideko Ohama, Kazuhiro Nouso, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Korenobu Hayama, Taeang Arai, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Kouji Joko, Kojiro Michitaka, Yoichi Hiasa, Masatoshi Kudo
Published 2021-02-01

Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis

by Atsushi Hiraoka, Takashi Kumada, Masanori Atsukawa, Masashi Hirooka, Kunihiko Tsuji, Toru Ishikawa, Koichi Takaguchi, Kazuya Kariyama, Ei Itobayashi, Kazuto Tajiri, Noritomo Shimada, Hiroshi Shibata, Hironori Ochi, Toshifumi Tada, Hidenori Toyoda, Kazuhiro Nouso, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Korenobu Hayama, Michitaka Imai, Kouji Joko, Yohei Koizumi, Yoichi Hiasa, Kojiro Michitaka, Masatoshi Kudo, the Real‐life Practice Experts for HCC (RELPEC) Study Group, HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
Published 2019-07-01

Impact of modified albumin–bilirubin grade on survival in patients with HCC who received lenvatinib

by Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Masanori Atsukawa, Masashi Hirooka, Kunihiko Tsuji, Toru Ishikawa, Koichi Takaguchi, Kazuya Kariyama, Ei Itobayashi, Kazuto Tajiri, Noritomo Shimada, Hiroshi Shibata, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Shinya Fukunishi, Hideko Ohama, Kazuhito Kawata, Joji Tani, Shinichiro Nakamura, Kazuhiro Nouso, Akemi Tsutsui, Takuya Nagano, Tanaka Takaaki, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Kouji Joko, Yohei Koizumi, Yoichi Hiasa, Real-life Practice Experts for HCC (RELPEC) Study Group and the HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
Published 2021-07-01

Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma

by Keisuke Koroki, Naoya Kanogawa, Susumu Maruta, Sadahisa Ogasawara, Yotaro Iino, Masamichi Obu, Tomomi Okubo, Norio Itokawa, Takahiro Maeda, Masanori Inoue, Yuki Haga, Atsuyoshi Seki, Shinichiro Okabe, Yoshihiro Koma, Ryosaku Azemoto, Masanori Atsukawa, Ei Itobayashi, Kenji Ito, Nobuyuki Sugiura, Hideaki Mizumoto, Hidemi Unozawa, Terunao Iwanaga, Takafumi Sakuma, Naoto Fujita, Hiroaki Kanzaki, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Tomoko Saito, Takayuki Kondo, Eiichiro Suzuki, Yoshihiko Ooka, Shingo Nakamoto, Akinobu Tawada, Tetsuhiro Chiba, Makoto Arai, Tatsuo Kanda, Hitoshi Maruyama, Jun Kato, Naoya Kato
Published 2021-04-01

Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study

by Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, Joji Tani, Kazuya Kariyama, Shinya Fukunishi, Masanori Atsukawa, Masashi Hirooka, Kunihiko Tsuji, Toru Ishikawa, Koichi Takaguchi, Ei Itobayashi, Kazuto Tajiri, Noritomo Shimada, Hiroshi Shibata, Hironori Ochi, Kazuhito Kawata, Satoshi Yasuda, Hidenori Toyoda, Tomoko Aoki, Takaaki Tanaka, Hideko Ohama, Kazuhiro Nouso, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Taeang Arai, Tomomi Okubo, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Koji Joko, Yoichi Hiasa, Masatoshi Kudo, The Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
Published 2021-08-01